By Alicia M. Jerome MS, RD, LD
For much of the 20th century, estrogen was considered foundational to women’s long-term health. Then, in 2002, it became something to fear.
Almost overnight, prescriptions plummeted. Headlines warned of cancer, stroke, and dementia. Women stopped therapy mid-course. Clinicians recalibrated quickly and often cautiously. What followed was not simply a shift in medical practice, but a shift in public perception. Estrogen was no longer protective. It was risky.
But what if the story is more complicated than that? What if the evidence was never as simple as we were led to believe?
The Data That Disrupted Everything
Before the early 2000s, observational studies painted a very different picture. The Framingham data suggested a 50 percent reduction in osteoporosis-related hip fractures among estrogen users.1 Other large cohorts reported substantial reductions in colon cancer risk.1 Cardiovascular outcomes appeared favorable. Bone density preservation was not subtle, it was measurable and clinically meaningful.
Then the Women’s Health Initiative (WHI) was stopped early.
The message that reached the public was clear: hormone therapy increased breast cancer risk by 26 percent.2 The nuance that the findings, “almost reached nominal statistical significance,” that absolute risk increases were small, that the median participant was 63 years old (well beyond the menopausal transition), and that only 13 percent had moderate or severe menopausal symptoms, were largely lost.1
A generation of women internalized a simplified conclusion: estrogen is dangerous.
The Missing Context: Who Was Actually Studied?
The median age of WHI participants was 63 years.2 More than two-thirds were overweight or obese.2 Most were not seeking treatment for active menopausal symptoms.2 This matters.
Menopause typically occurs around age 51.1 Starting hormone therapy a decade after ovarian hormone withdrawal is biologically different from initiating it near the onset of symptoms. Subsequent analyses of WHI data suggested that women who began therapy within ten years of menopause had reduced coronary artery disease risk, while those who started later experienced slightly increased risk.1 The timing hypothesis emerged. But by then, the damage to public confidence had been done.
Breast Cancer: Relative Risk vs. Absolute Risk
Few topics provoke as much fear as breast cancer. Yet risk interpretation requires precision.
In one widely cited reanalysis, the increased number of breast cancer cases among 100 women taking estrogen for ten or more years was 0.6 cases.3 Not 6. Not 60. Less than one additional case per 100 women.
Meanwhile, the relative risk of tobacco smoking and lung cancer exceeds 26-fold and yet we do not see the same reflexive panic in discussions of far smaller risk differentials.1
Of 20 studies published between 1975 and 2000 examining hormone therapy and breast cancer, 80 percent showed no increased risk.4 The hypothesis that estrogen is a direct causal driver of breast cancer fails to meet even one of the Bradford Hill criteria for causation.1
This does not mean estrogen is risk-free. It means the narrative may have misinterpreted the evidence.
The Symptoms We Minimized
Nearly 100 percent of postmenopausal women will develop some degree of urogenital atrophy.5 Vasomotor symptoms, such as hot flashes, last a median of 7.4 years.6 That’s not a brief inconvenience, but a significant physiological transition. In surveys of women physicians, up to 90 percent reported that menopausal symptoms affected their work lives.7
And yet, in the study that reshaped public opinion, quality of life was measured using a “rating of well-being” rather than the frequency of hot flushes or sleep disruption.2 When a wellness scale instead of risk and discomfort dominate the conversation, negative aspects of quality of life can quietly recede.
Bone, Brain, and Heart: A Broader View
Women over age 50 have four times the rate of osteoporosis as men.8 Twenty to twenty-five percent of older adults who experience hip fractures die within a year.9 WHI investigators themselves reported a 33% reduction in hip fractures among women on hormone therapy.2
Heart disease remains responsible for one in five female deaths.1 Most observational data suggest around a 50% reduction in coronary events among women using unopposed oral estrogen when initiated near menopause.10
Cognitive outcomes are more complex. Dementia risk appears influenced by timing, baseline neuronal health, and age at initiation.1 Estrogen increases enzymes necessary for acetylcholine synthesis, a neurotransmitter reduced by up to 90% in Alzheimer’s disease.1 Some meta-analyses report overall reduced dementia risk. Others highlight increased risk when therapy begins later in life. Again, timing and context matter.
Why This Still Matters
According to the FDA, more than 80% of American women over age 45 report at least one menopausal symptom.1 Yet only about 10% report using menopausal hormone therapy.1 Fear shapes decisions, sometimes appropriately, sometimes disproportionately.
The conversation around estrogen has often been framed as black or white: safe or unsafe, protective or harmful. But biology is rarely binary. Risk is rarely uniform. And population-level data do not always translate neatly to individual decision-making.
The deeper question may not be whether estrogen is “good” or “bad,” but whether we have interpreted its risks and benefits with sufficient precision for the benefit of the individual woman.
The book that inspired these questions does not argue for universal hormone therapy. It argues for rigorous evidence appraisal, proportional risk interpretation, and a willingness to revisit assumptions when new analyses challenge established narratives. In an era where medical headlines travel faster than nuance, those may be the most important lessons of all.
Explore these ideas and earn 16 CPE hours while deepening your understanding of estrogen, menopause, and risk interpretation through taking Helm Publishing’s Estrogen Matters self-study course. It is designed to help nutrition professionals navigate the most misunderstood topics in women’s health with clarity and confidence.
References:
1. Bluming, Avrum, and Carol Tavris. Estrogen Matters: Why Taking Hormones in Menopause Can Improve and Lengthen Women’s Lives -- without Raising the Risk of Breast Cancer. Little, Brown Spark, 2024.
2. Rossouw, Jacques E., Garnet L. Anderson, Robert L. Prentice, et al. “Risks and Benefits of Estrogen Plus Progestin on Healthy Postmenopausal Women: Principal Results from the Women’s Health Initiative Randomized Controlled Trial.” JAMA 288 (2002): 321–333.
3. Shapiro S, Farmer RDT, Seaman H, et al. Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies. Part 1. The Collaborative Reanalysis. J Fam Plann Reprod Health Care. 2011; 37:103-9.
4. Bush TL, Whiteman M, Flaws JA. Hormone replacement therapy and breast cancer: A qualitative review. Obstet Gynecol. 2001;98:498-508.
5. Shifren JL, Crandall CJ, Manson JE. Menopausal hormone therapy. JAMA. 2019; 321:2458-59.
6. Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175:531-539.
7. Hill, Amelia, “Female Doctors in Menopause Retiring Early Due to Sexism, Study Says,” The Guardian, August 5, 2020.
8. Alswat KA. Gender disparities in osteoporosis. J Clin Med Res. 2017;9:382-87.
9. Brauer CA, Coca-Perraillon M, Cutler DM, et al. Incidence and mortality of hip fractures in the United States. JAMA 2009;302:1573-79.
10. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA. 1991;265:1861-67.